{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.19","upperLimit":"136.00","value":"54.4"},{"groupId":"OG001","lowerLimit":"14.00","upperLimit":"107.00","value":"61.5"},{"groupId":"OG002","lowerLimit":"19.10","upperLimit":"293.00","value":"23.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"The median (min, max) of the peak plasma concentration of entinostat stratified by study part, dose level. Time points were assessed at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1.","dispersionType":"Full Range","groups":[{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 3 mg/m2","id":"OG000","title":"Stratum 1 With 3 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 4 mg/m2","id":"OG001","title":"Stratum 1 With 4 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors without bone marrow involvement, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at the RP2D (4 mg/m2)","id":"OG002","title":"PK Part With 4 mg/m²"}],"paramType":"MEDIAN","populationDescription":"All eligible enrolled patients.","reportingStatus":"POSTED","timeFrame":"Up to 96 hours","title":"Peak Plasma Concentration of Entinostat: C-Max","type":"PRIMARY","unitOfMeasure":"ng/ml"}